Power Hour Surge: Biotech Breakouts, Digital Disruptors, and Small-Cap Sizzlers

August 25, 2025

DENVER, Colo., Aug 25, 2025 (247marketnews.com)- Since we’re seeing some of the best trading action in weeks, I’m kicking off power hour reporting early.

Inno Holdings (NASDAQ:INHD), which recently completed its IPO, is staying on the radar as it expands its innovative construction technology offerings, including 3D-printed building solutions. Traders are watching for updates on revenue scaling and commercial deployments in key Sun Belt regions. Today’s steady rise into the close may hint at earnings optimism ahead of its next quarterly update.

Tilray Brands (NASDAQ:TLRY) has been setting off our alerts since dipping below $0.48 in July, and the stock continues to grind higher into the close. With cannabis sentiment rebounding and U.S. rescheduling rumors still floating, TLRY could benefit from renewed retail interest, especially if federal reform headlines resurface in the weeks ahead.

Offerpad Solutions (NYSE:OPAD) is trading higher today as speculation swirls around housing market stabilization and potential M&A interest among proptech names. The company has been cutting costs and pivoting toward profitable markets and today’s action suggests investors are betting on a bounce from deeply oversold levels.

Last week, we stated that Tharimmune (NASDAQ:THAR) looked like it was a strong candidate to continue gaining after recent clinical updates tied to its liver disease pipeline. The biotech is focused on orphan and underserved indications, and traders are keeping a close watch for any partnership or IND announcements that could reignite momentum.

LIXTE Biotechnology (NASDAQ:LIXT) is quietly becoming a biotech story with serious upside. Its lead compound, LB-100, has cleared early-phase safety markers and is now entering OCCC trials in collaboration with GlaxoSmithKline (NYSE:GSK).

With patents extending into the 2040s and a clinical strategy that complements both chemo and immunotherapy in treatment-resistant cancers, LIXTE is building a portfolio that could fill key gaps in Big Pharma pipelines and investors are starting to connect the dots.

OSR Holdings (NASDAQ:OSRH) was one to watch, this morning, and continues to move on speculative interest, pushing fresh intraday highs. The company’s biomedical innovation focus, paired with low float dynamics, is attracting retail momentum.

ESSA Pharma (NASDAQ:EPIX) is under the microscope following news of its acquisition by XenoTherapeutics, supported by XOMA Royalty (NASDAQ:XOMA). As deal details emerge, investors are awaiting clarity on pipeline rights, future milestone payments, and how ESSA’s prostate cancer assets may fit into the acquirer’s strategy.

Sharps Technology (NASDAQ:STSS) is grabbing institutional and retail headlines alike with its $400 million private placement to build what it calls the world’s largest Solana (SOL)-based digital asset treasury. With big-name backers like Pantera, ParaFi, and CoinFund, the company plans to acquire SOL both on the open market and directly from the Solana Foundation at a 15% discount, per a signed LOI.

Executive Chair Paul Danner called Sharps “well positioned to become a leading SOL treasury,” while CIO Alice Zhang said Solana “defines the standard for digital infrastructure.” With Solana boasting 7% staking yields and $6B+ in daily volume, STSS could become a benchmark for corporate token treasuries and the market is responding accordingly.

Capstone (NASDAQ:CAPS) just closed its Carolina Stone Products acquisition, adding ~$11 million in trailing revenue and boosting margins into a 24.4% gross margin print for Q2. The building products distributor is executing on a disciplined M&A playbook, targeting deals in the 4–6× EBITDA range, and expects at least one more acquisition by year-end.

CEO Matthew Lipman says the deal puts Capstone on pace for a $100 million revenue run rate entering 2026. Today’s power hour action reflects investor appreciation for both growth and margin-expanding discipline, a rare combo in the small-cap construction space.

Incannex (NASDAQ:IXHL), an innovator in psychedelic-assisted therapies and cannabinoid-based treatments, is showing signs of quiet accumulation today. Investors are positioning ahead of clinical trial updates, including its ongoing generalized anxiety disorder program involving psilocybin therapy. Low float and catalyst-driven speculation could spark after-hours volume.

HCW Biologics (NASDAQ:HCWB) is pacing the biotech space as it builds into its September 12th presentation at Nova Southeastern University, where it will unveil preclinical data on its second-generation immune checkpoint inhibitor. Developed on its proprietary TRBC platform and fused with pembrolizumab (KEYTRUDA), the molecule targets hard-to-treat cancers like pancreatic and ovarian tumors, and could address limitations of existing checkpoint inhibitors by neutralizing TGF-β and activating immune infiltration.

With global checkpoint inhibitor sales exceeding $40 billion in 2024, HCW’s preclinical outperformance vs. pembrolizumab monotherapy has traders watching closely. Volume is picking up into the power hour, and after-hours chatter could intensify as investors speculate on IND timelines.

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.

 

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (INHD, TLRY, OPAD, THAR, LIXT, OSRH)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.